How do we perform intrauterine transfusions?
© 2023 AABB..
BACKGROUND: Intrauterine transfusion (IUT) is an invasive but critical and potentially life-saving intervention for severe fetal anemia with demonstrated improvement in outcomes. The fetus is vulnerable to hemodynamic alterations and transfusion-related adverse events; therefore, special consideration must be given to blood component selection and modification. There is widespread IUT practice variability, and existing guidance primarily relies on expert opinion and single center experiences.
STUDY DESIGN AND METHODS: Experts in Maternal Fetal Medicine, Pediatric Hematology, and Transfusion Medicine from centers across the United States, collectively performing about 120 IUT annually, offer a multidisciplinary perspective on the performance of IUT and preparation of blood components. This perspective includes strategies for identifying an at-risk fetus, communicating between disciplines, determining the necessary blood volume, selecting and processing blood components, documenting the procedure in medical record, and managing the neonate.
RESULTS: Identifying an at-risk fetus relies on review of the clinical history, non-invasive monitoring, and laboratory evaluation. We recommend the use of relatively fresh, group O, cytomegalovirus-safe, freshly irradiated, red blood cells (RBC) that are Hemoglobin S negative and antigen-negative for any maternal antibody, if indicated. These RBC units should be concentrated to remove additives and increase the hematocrit thus minimizing fluctuations in fetal volume status. The units intended for IUT should be labeled clearly and the documentation of transfusion differentiated in the maternal medical record.
DISCUSSION: An awareness of the technical, logistical, and regulatory considerations for IUT performance will facilitate improved communication and patient care, especially when rare units of RBC are required.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:63 |
|---|---|
| Enthalten in: |
Transfusion - 63(2023), 12 vom: 26. Dez., Seite 2214-2224 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Crowe, Elizabeth P [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Blood component preparation |
|---|
| Anmerkungen: |
Date Completed 07.12.2023 Date Revised 01.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/trf.17570 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363805575 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363805575 | ||
| 003 | DE-627 | ||
| 005 | 20240301232108.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/trf.17570 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1313.xml |
| 035 | |a (DE-627)NLM363805575 | ||
| 035 | |a (NLM)37888489 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Crowe, Elizabeth P |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a How do we perform intrauterine transfusions? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2023 | ||
| 500 | |a Date Revised 01.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 AABB. | ||
| 520 | |a BACKGROUND: Intrauterine transfusion (IUT) is an invasive but critical and potentially life-saving intervention for severe fetal anemia with demonstrated improvement in outcomes. The fetus is vulnerable to hemodynamic alterations and transfusion-related adverse events; therefore, special consideration must be given to blood component selection and modification. There is widespread IUT practice variability, and existing guidance primarily relies on expert opinion and single center experiences | ||
| 520 | |a STUDY DESIGN AND METHODS: Experts in Maternal Fetal Medicine, Pediatric Hematology, and Transfusion Medicine from centers across the United States, collectively performing about 120 IUT annually, offer a multidisciplinary perspective on the performance of IUT and preparation of blood components. This perspective includes strategies for identifying an at-risk fetus, communicating between disciplines, determining the necessary blood volume, selecting and processing blood components, documenting the procedure in medical record, and managing the neonate | ||
| 520 | |a RESULTS: Identifying an at-risk fetus relies on review of the clinical history, non-invasive monitoring, and laboratory evaluation. We recommend the use of relatively fresh, group O, cytomegalovirus-safe, freshly irradiated, red blood cells (RBC) that are Hemoglobin S negative and antigen-negative for any maternal antibody, if indicated. These RBC units should be concentrated to remove additives and increase the hematocrit thus minimizing fluctuations in fetal volume status. The units intended for IUT should be labeled clearly and the documentation of transfusion differentiated in the maternal medical record | ||
| 520 | |a DISCUSSION: An awareness of the technical, logistical, and regulatory considerations for IUT performance will facilitate improved communication and patient care, especially when rare units of RBC are required | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a blood component preparation | |
| 650 | 4 | |a fetal anemia | |
| 650 | 4 | |a maternal-fetal medicine | |
| 650 | 4 | |a pregnancy | |
| 700 | 1 | |a Hasan, Rida |e verfasserin |4 aut | |
| 700 | 1 | |a Saifee, Nabiha H |e verfasserin |4 aut | |
| 700 | 1 | |a Bakhtary, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Jena L |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Velez, Juan M |e verfasserin |4 aut | |
| 700 | 1 | |a Goel, Ruchika |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transfusion |d 1961 |g 63(2023), 12 vom: 26. Dez., Seite 2214-2224 |w (DE-627)NLM00001107X |x 1537-2995 |7 nnns |
| 773 | 1 | 8 | |g volume:63 |g year:2023 |g number:12 |g day:26 |g month:12 |g pages:2214-2224 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/trf.17570 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 63 |j 2023 |e 12 |b 26 |c 12 |h 2214-2224 | ||